NEWPORT, Ky., Oct. 29 -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceuticalcompany with both development and commercial capabilities focused on women's healthcare and pain management, announced today the completion of $50 million in equity financing. The round was led by Longitude Capital with
Michael J. Valentino, President and CEO commented, "I am extremely pleased to have secured additional financial resources which will be used to support our ongoing development and commercialization strategy for our emerging product portfolio."
In June 2009, Xanodyne received Food and Drug Administration (FDA) approval for Zipsor™ (diclofenac potassium) Liquid Filled Capsules, a new treatment option for relief of mild to moderate acute pain in adults (18 years of age or older). Zipsor was launched nationally to physicians and patients in September.
In addition, the company expects FDA action soon on Lysteda™ (formerly XP12B), an oral tranexamic acid product under priority review. If approved, Lysteda would be the first and only oral therapeutic agent indicated specifically for the treatment of women suffering from cyclic heavy menstrual bleeding.
Valentino added, "The continued commitment from our investor groups allows us to remain focused on aggressively executing our product commercialization plans and optimizing the other assets in our portfolio."
Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of products consisting of prescription pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.
SOURCE Xanodyne Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...
Therapeutic drug monitoring is measuring drug concentrations at specific intervals in a patient's ...View All